Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436
SEATTLE, WA / ACCESSWIRE / October 26, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology...
2026 Calls for a Global Health System Connectivity Compact: EHR/EMR, Interoperability, and Cybersecurity Vendors Urged to Protect Continuity of Care During Conflict and Recovery